LVAD DT denied as non-formulary by Aetna?

Aetna's specific coverage criteria for lvad dt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies LVAD Destination Therapy as Non-Formulary

Unlike prescription drugs, LVAD destination therapy is typically covered under the medical benefit — not the pharmacy benefit — and is subject to medical coverage policies rather than a drug formulary. A non-formulary denial in this context most likely means that Aetna's medical coverage policy does not include LVAD-DT for the specific indication or patient profile presented, or that the specific device model is not listed in Aetna's approved device policy. This is functionally equivalent to a medical-necessity or coverage-exclusion denial and should be treated with the same urgency given that LVAD-DT is a life-sustaining intervention.

## Why This Denial Is Appealable

Coverage-exclusion and non-covered-service denials are fully appealable. ACA §2719 provides access to external review for coverage determinations with a medical basis. ERISA §503 requires full-and-fair review for employer-sponsored plans. File an internal appeal within the deadline on the denial notice. Request external review within approximately four months of exhausting internal remedies. Given the life-sustaining nature of LVAD-DT, request expedited (72-hour) review at both stages on the grounds that delay would seriously jeopardize the patient's health or life.

## The Concrete Appeal Process

1. Obtain Aetna's specific coverage determination: request the written coverage policy or Clinical Policy Bulletin that governs LVAD and mechanical circulatory support devices. 2. Identify the specific basis for non-formulary/non-covered determination: is it the device model, the indication, or the patient's clinical profile? 3. File an internal appeal addressing the specific non-coverage basis with complete clinical and regulatory documentation. 4. Request expedited external IRO review if clinical urgency warrants it.

## Documentation to Gather

• FDA device approval documentation: the FDA-approved labeling and PMA or 510(k) clearance for the specific LVAD device model, confirming its approved indication includes destination therapy.
• Aetna's coverage policy: the specific Clinical Policy Bulletin or medical coverage policy Aetna applied — so you can respond to each criterion.
• Cardiology team's medical-necessity letter: a comprehensive letter from the treating heart failure specialist explaining why LVAD-DT is medically necessary for this patient, referencing the FDA-approved indication and the applicable cardiovascular guideline organization (such as ACC/AHA) by name.
• Advanced heart failure diagnosis and transplant ineligibility: chart notes confirming disease stage, clinical trajectory, and formal transplant ineligibility documentation.
• Prior therapy optimization history: documentation of advanced medical therapies tried, with dates and clinical outcomes, confirming that less-invasive options have been appropriately pursued.

## Criteria-Mapping Structure

For a non-formulary or non-covered LVAD-DT denial, the appeal must establish two things: (1) the device is FDA-approved for the specific indication, and (2) the patient meets the clinical criteria in Aetna's own coverage policy. Organize the appeal around these two pillars. Attach FDA labeling, the cardiology letter, transplant ineligibility documentation, and the prior therapy record. Request that Aetna specify in writing exactly which coverage criterion was not met — if the denial is vague, that vagueness is itself appealable under ERISA's full-and-fair review standard.